ArticlePediatrics international : official journal of the Japan Pediatric Society
MIS-C Overlap, Not Prior COVID-19 Itself, Drives Treatment Escalation in Kawasaki Disease: A Nationwide Cohort Study.
Article in Pediatrics international : official journal of the Japan Pediatric Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundWhether prior coronavirus disease 2019 (COVID-19) independently influences treatment response in children with Kawasaki disease (KD) is unclear, as prior reports may have been confounded by overlap with multisystem inflammatory syndrome in children (MIS-C). We investigated this in a nationwide cohort, accounting for these factors.
methodsWe conducted a retrospective cohort study using the Korean National Health Insurance Service database. Children diagnosed with KD on or after January 1, 2020 who received IVIG within 7 days were included. Prior COVID-19 was defined as documented infection within 3 months before KD diagnosis. The primary outcome was second-line treatment within 7 days after initial IVIG (composite of second IVIG or additional steroid). 1:1 propensity score matching was performed using age, sex, MIS-C status, and steroid use with initial IVIG.
resultsAmong 6572 eligible children, 512 had prior COVID-19; 431 patients were matched per group. Second-line treatment occurred in 32/431 (7.4%) versus 23/431 (5.3%) (p = 0.265). Prior COVID-19 was not independently associated with second-line treatment (adjusted HR 1.42; 95% CI 0.83-2.43). In subgroup analysis, elevated risk was confined to children with concurrent MIS-C (HR 3.01; 95% CI 1.34-6.74); prior COVID-19 without MIS-C showed no increase (HR 1.18; 95% CI 0.66-2.11). Sensitivity analyses excluding MIS-C and restricted to 2022 onward were consistent.
conclusionsPrior COVID-19 alone was not independently associated with second-line treatment once MIS-C overlap and concurrent steroid use were accounted for. The elevated treatment escalation rate appeared driven primarily by MIS-C, highlighting the importance of distinguishing MIS-C from classic KD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.